FMT for immunotherapy-refractory melanoma


A phase I clinical trial has assessed the use of faecal microbiota transplantation (FMT) and re-induction of anti-PD1 immunotherapy in patients with immunotherapy-refractory melanoma. In this safety and feasibility trial, ten patients with metastatic melanoma who had progressed on anti-PD1 immunotherapy were administered with orally ingested antibiotics for 72 hours, and FMT was then performed via both colonoscopy and administration of oral stool capsules, followed by re-induction of anti-PD-1 immunotherapy. Two patients achieved partial responses, and one patient achieved a complete response. Favourable changes in immune cell infiltrates and gene expression profiles were observed in the gut lamina propria and the tumour microenvironment after FMT. The FMT donors were two individuals previously treated with anti-PD1 therapy for metastatic melanoma and had achieved a complete response.


Original article

  1. Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science (2020)

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Jordan Hindson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hindson, J. FMT for immunotherapy-refractory melanoma. Nat Rev Gastroenterol Hepatol 18, 82 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing